The balance between two immune signaling molecules — CXCL13 and BAFF — may help identify the hard-to-treat inflammation in the brain and spinal cord that’s thought to be a major driver of disability progression in multiple sclerosis (MS), a study found. The findings may help identify which patients are most likely to benefit from BTK […]
The post New biomarker may help identify MS patients for BTK inhibitors appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com